Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLK NASDAQ:ALXO NASDAQ:BCLI NASDAQ:HOWL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.24 million shsN/AALXOALX Oncology$0.49-3.7%$0.48$0.40▼$6.84$27.02M1.11902,030 shs364,748 shsBCLIBrainstorm Cell Therapeutics$0.77-8.3%$1.17$0.59▼$6.00$7.58M0.22418,408 shs178,458 shsHOWLWerewolf Therapeutics$1.39-1.4%$1.19$0.60▼$4.18$61.92M0.62443,024 shs281,722 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+1.26%-52.25%ALXOALX Oncology0.00%+4.99%+4.67%-10.53%-91.76%BCLIBrainstorm Cell Therapeutics0.00%-28.75%-29.92%-0.58%-83.54%HOWLWerewolf Therapeutics0.00%+18.49%+18.49%+69.92%-48.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos3.4069 of 5 stars3.20.00.04.70.02.51.3ALXOALX Oncology3.3074 of 5 stars3.43.00.00.01.14.21.3BCLIBrainstorm Cell Therapeutics1.1675 of 5 stars0.02.00.04.71.60.80.6HOWLWerewolf Therapeutics3.4897 of 5 stars3.55.00.00.00.05.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.33Hold$3.00811.58% UpsideALXOALX Oncology 2.71Moderate Buy$3.30576.23% UpsideBCLIBrainstorm Cell Therapeutics 0.00N/AN/AN/AHOWLWerewolf Therapeutics 3.00Buy$8.33499.52% UpsideCurrent Analyst Ratings BreakdownLatest BCLI, ALLK, ALXO, and HOWL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025ALXOALX OncologyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/9/2025ALXOALX OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.005/9/2025HOWLWerewolf TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/AALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/AHOWLWerewolf Therapeutics$1.88M33.18N/AN/A$1.65 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)ALXOALX Oncology-$134.85M-$2.47N/AN/AN/AN/A-104.43%-77.74%8/14/2025 (Estimated)BCLIBrainstorm Cell Therapeutics-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)HOWLWerewolf Therapeutics-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)Latest BCLI, ALLK, ALXO, and HOWL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ALXOALX Oncology-$0.46N/AN/AN/AN/AN/A8/14/2025Q2 2025HOWLWerewolf Therapeutics-$0.50N/AN/AN/AN/AN/A8/13/2025Q2 2025BCLIBrainstorm Cell Therapeutics-$0.41N/AN/AN/AN/AN/A8/6/2025Q2 2025ALLKAllakos-$0.24N/AN/AN/AN/AN/A5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/8/2025Q1 2025ALXOALX Oncology-$0.47-$0.58-$0.11-$0.58N/AN/A5/8/2025Q1 2025HOWLWerewolf Therapeutics-$0.44-$0.40+$0.04-$0.40$0.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/AALXOALX OncologyN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08ALXOALX Oncology0.095.475.47BCLIBrainstorm Cell TherapeuticsN/A0.210.21HOWLWerewolf Therapeutics0.468.098.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%ALXOALX Oncology97.97%BCLIBrainstorm Cell Therapeutics14.33%HOWLWerewolf Therapeutics64.84%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%ALXOALX Oncology21.00%BCLIBrainstorm Cell Therapeutics11.15%HOWLWerewolf Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableALXOALX Oncology4053.40 million42.18 millionOptionableBCLIBrainstorm Cell Therapeutics409.84 million8.74 millionOptionableHOWLWerewolf Therapeutics4044.87 million34.28 millionOptionableBCLI, ALLK, ALXO, and HOWL HeadlinesRecent News About These CompaniesHowling Hits: The Ultimate List of Must-Watch Werewolf MoviesJuly 17, 2025 | msn.comWerewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research SummitJuly 9, 2025 | globenewswire.comWerewolf Therapeutics, Inc. (HOWL) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comWerewolf Therapeutics to Participate in the BIO International ConventionJune 12, 2025 | globenewswire.comWerewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should KnowMay 29, 2025 | zacks.comWerewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWerewolf Therapeutics’ SWOT analysis: innovative platform drives stock potentialMay 24, 2025 | investing.comWerewolf Therapeutics Stock Price, Quotes and ForecastsMay 20, 2025 | benzinga.comHonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124May 20, 2025 | globenewswire.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Acquires $159,288.22 in StockMay 15, 2025 | insidertrades.comWerewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development SummitMay 13, 2025 | globenewswire.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | finanznachrichten.deWerewolf Therapeutics Announces Q1 2025 Financial ResultsMay 9, 2025 | msn.comWerewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comWerewolf Therapeutics reports progress on IBD treatmentMay 6, 2025 | investing.comWerewolf Therapeutics to Participate in Upcoming Investor ConferencesMay 5, 2025 | globenewswire.comListening to the Desert’s “Werewolf Mouse” Reveals the Complex World of BioacousticsMay 1, 2025 | marfapublicradio.orgMEarnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to DeclineApril 25, 2025 | zacks.comWerewolf Therapeutics appoints Bloom as Chief Business OfficerApril 17, 2025 | markets.businessinsider.comWerewolf Therapeutics Appoints Steven Bloom as Chief Business OfficerApril 17, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCLI, ALLK, ALXO, and HOWL Company DescriptionsAllakos NASDAQ:ALLKAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.ALX Oncology NASDAQ:ALXO$0.49 -0.02 (-3.67%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Brainstorm Cell Therapeutics NASDAQ:BCLI$0.77 -0.07 (-8.33%) As of 12:11 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Werewolf Therapeutics NASDAQ:HOWL$1.39 -0.02 (-1.42%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
